Related Experiment Videos

Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients

T L Levin1, S Sheth, W E Berdon

  • 1Department of Radiology, Columbia-Presbyterian Medical Center, Babies & Children's Hospital, 3959 Broadway, BHN 3-318, New York, NY 10032, USA.

Pediatric Radiology
|November 1, 1995
PubMed

Insights

Deferoxamine chelation therapy can cause skeletal abnormalities in thalassemia patients, especially when initiated in infancy. These bone changes, including vertebral flattening, resemble Scheuermann disease.

Area of Science:

  • Hematology
  • Pediatric Endocrinology
  • Radiology

Background:

  • Deferoxamine is a critical iron chelation therapy for hypertransfused thalassemia patients.
  • Skeletal growth abnormalities have been suspected with long-term deferoxamine use.

Observation:

  • Radiographic review of seven hypertransfused thalassemia patients.
  • Serial spinal imaging in two patients treated from infancy was analyzed.

Findings:

  • Patients receiving early, high-dose deferoxamine exhibited rachitic-like changes in long bones and vertebral body flattening.
  • Vertebral bodies progressed from normal to bulbous, then flattened, resembling a milder Scheuermann disease.
  • Bone changes were distinct from, but reminiscent of, post-radiation effects.

Implications:

  • Early and high-dose deferoxamine therapy may pose a risk for skeletal development in pediatric patients.
  • Monitoring skeletal growth is crucial for thalassemia patients undergoing long-term chelation.
  • Further research into optimizing chelation protocols to mitigate bone toxicity is warranted.

Related Concept Videos